Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
तुलना करने के लिए मीट्रिक्स | QNTM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधQNTMपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1.4x | −1.6x | −0.5x | |
PEG अनुपात | - | −0.03 | 0.00 | |
क़ीमत/बुक | 5.2x | 0.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.6x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 222.1% | 53.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 17.3% | 8.4% | अनलॉक करें |